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Epigenetic analysis leads to identiﬁcation of
HNF1B as a subtype-speciﬁc susceptibility
gene for ovarian cancer
Hui Shen, Brooke L. Fridley, Honglin Song et al.w
HNF1B is overexpressed in clear cell epithelial ovarian cancer, and we observed epigenetic
silencing in serous epithelial ovarian cancer, leading us to hypothesize that variation in this
gene differentially associates with epithelial ovarian cancer risk according to histological
subtype. Here we comprehensively map variation in HNF1B with respect to epithelial ovarian
cancer risk and analyse DNA methylation and expression proﬁles across histological subtypes.
Different single-nucleotide polymorphisms associate with invasive serous (rs7405776 odds
ratio (OR)¼ 1.13, P¼ 3.1 10 10) and clear cell (rs11651755 OR¼0.77, P¼ 1.6 10 8)
epithelial ovarian cancer. Risk alleles for the serous subtype associate with higher
HNF1B-promoter methylation in these tumours. Unmethylated, expressed HNF1B, primarily
present in clear cell tumours, coincides with a CpG island methylator phenotype affecting
numerous other promoters throughout the genome. Different variants in HNF1B associate with
risk of serous and clear cell epithelial ovarian cancer; DNA methylation and expression pat-
terns are also notably distinct between these subtypes. These ﬁndings underscore distinct
mechanisms driving different epithelial ovarian cancer histological subtypes.
wA full list of authors and their afﬁliations appears at the end of the paper.
DOI: 10.1038/ncomms2629 OPEN
NATURE COMMUNICATIONS | 4:1628 | DOI: 10.1038/ncomms2629 | www.nature.com/naturecommunications 1
& 2013 Macmillan Publishers Limited. All rights reserved.
I
nvasive epithelial ovarian cancer (EOC) has a strong heritable
component1, with an approximate three-fold increased risk
associated with a ﬁrst-degree family history2. Much of the
excess familial risk observed for EOC is unexplained3, and efforts
to identify common susceptibility genes have proven to be
difﬁcult. Seven regions harbouring susceptibility single-nucleotide
polymorphisms (SNPs) for ovarian cancer have been identiﬁed
through genome-wide association studies4–7 thus far, but
candidate gene studies have been largely unsuccessful8.
The Cancer Genome Atlas (TCGA) has fully characterized
more than 500 serous EOC cases with respect to somatic
mutation, DNA methylation, mRNA expression and germline
genetic variants9. These data are publicly available and can be
analysed to identify candidate genes for association studies of the
disease.
We conducted such an analysis of TCGA data and found a
unique expression and methylation pattern of HNF1B character-
ized by downregulation of expression in most cases, with
epigenetic silencing in about half of the cases, suggesting it might
have a role in the serous subtype of ovarian cancer. In contrast,
HNF1B overexpression is common in clear cell ovarian cancer10.
The HNF1B gene (formerly known as TCF2) encodes a POU-
domain containing a tissue-speciﬁc transcription factor, and
mutations in the gene cause maturity onset diabetes of the young
type 5 (ref. 11). HNF1B is also a susceptibility gene for type II
diabetes12,13, prostate cancer12,14–16 and uterine cancer17.
We report here on our comprehensive characterization of this
gene in ovarian cancer and show evidence of a differential effect of
HNF1B on the serous and clear cell subtypes of ovarian cancer. It
appears that HNF1B has a loss-of-function role in serous and a
gain-of-function role in clear cell ovarian cancers, and variants in
this gene differentially affect genetic susceptibility to these subtypes.
Results
DNA methylation/expression analysis. From TCGA data (see
Methods), HNF1B was observed to be epigenetically silenced in
approximately half of the 576 primary serous ovarian tumours
and downregulated by another mechanism in most of the other
tumours, whereas no evidence of methylation was seen in the
normal fallopian tube samples (Fig. 1a, Supplementary Fig. S1)
available from TCGA. We further assessed HNF1B-promoter
methylation in an independent data set (OCRF panel; see
Methods) and found the promoter region to be methylated in
42% of serous tumours and in none of the clear cell ovarian
tumours (Fig. 1b). The pattern in serous tumours, in contrast to
clear cell cancers, led to the evaluation of HNF1B as a candidate
subtype-speciﬁc susceptibility gene for ovarian cancer.
SNP analysis. With all invasive cancer subtypes considered
together, we found no genome-wide signiﬁcant (Po5 10 8)
HNF1B SNP associations among women of European ancestry
(Table 1; Supplementary Data S1). However, when analyses were
stratiﬁed by histological subtype, we observed genome-wide
signiﬁcant results for both serous and clear cell EOC subtypes,
but with risk associations in opposite directions. The association
was similar for high- and low-grade serous cancers. There was no
evidence of association for mucinous or endometrioid subtypes
(Fig. 1c). Associations in the non-European populations are
shown in Supplementary Table S2.
Minor alleles at nine SNPs, six genotyped and three imputed,
were associated with increased risk of invasive serous ovarian
cancer at Po5 10 8 (Table 1). The risk signal spanned a
21.4-kb region from the 50 untranslated region (UTR) through
part of intron 4 of HNF1B (Fig. 1c). The most strongly associated
SNP for invasive serous ovarian cancer (rs7405776, minor allele
frequency (MAF) 36%) conferred a 13% increased risk per minor
allele (P¼ 3.1 10 10; Table 1, Supplementary Fig. S2A). The
signals of this SNP and the eight other genome-wide signiﬁcant
SNPs were indistinguishable, given the linkage disequilibrium and
resulting haplotype structure (Supplementary Figs S3, S4 and S5).
For the clear cell subtype, rs11651755 (MAF 45%) was asso-
ciated with a 23% decreased risk of disease at a genome-wide
signiﬁcant level (P¼ 2 10 8; Table 1, Supplementary Fig. S2B).
This signal was distinct from the nine signiﬁcant SNPs
for invasive serous cancer (Table 1). The odds against the
serous-associated SNP, rs7405776, as the true best hit for clear
cell ovarian cancer were 244:1. Conversely, the odds against the
clear cell SNP, rs11651755, as the true best hit for serous were
1808:1. Further, when rs11651755 and rs7405776 were jointly
modelled, the signal for clear cell cancer was driven completely
by rs11651755, whereas that for the serous disease was driven by
rs7405776 (Table 1). The clear cell SNP (rs11651755) sits on ﬁve
haplotypes, only three of which also contain the serous SNP
(rs7405776; Supplementary Fig. S5). Thus, different SNPs in the
HNF1B gene regions explain the associations observed for serous
and clear cell ovarian cancer.
DNA methylation and protein expression. The identiﬁcation of
HNF1B as a susceptibility gene for serous and clear cell ovarian
cancer led us to further evaluate the relationship between HNF1B-
promoter DNA methylation, protein expression and histological
subtype. Immunohistochemistry (IHC) analysis for HNF1B protein
expression in 1,149 ovarian cancers from the Ovarian Tumor Tissue
Analysis Consortium, and DNA-methylation analysis on 269 of
these tumours, revealed that the majority of clear cell tumours
expressed the HNF1B protein and were unmethylated at the
HNF1B promoter, whereas the majority of serous tumours lacked
HNF1B protein expression and displayed frequent HNF1B-pro-
moter methylation (Fig. 2, Supplementary Fig. S6).
Although most clear cell tumours were devoid of HNF1B-pro-
moter methylation, they revealed a surprisingly high frequency of
CpG island hypermethylation at other sites across the genome,
indicative of a CpG island methylator phenotype (CIMP). The few
clear cell tumours lacking HNF1B expression exhibited HNF1B-
promoter methylation, and a correspondingly low frequency of
CpG island methylation throughout the genome, similar to the
serous subtype (Fig. 2). HNF1B expression and CIMP methylation
are strongly associated (P¼ 3 10 16; Fig. 2). Further, minimal
hypermethylation is observed in serous tumours overall, but
HNF1B is one notable exception (Supplementary Fig. S7).
DNA methylation and genotype. We further investigated the
relationship between risk allele genotypes and HNF1B DNA
methylation in 231 serous ovarian cancers. The top serous risk
SNP, rs7405776, showed only a borderline association with
increased promoter methylation (P¼ 0.07; Fig. 3). Intriguingly,
the association between SNPs in HNF1B and HNF1B-promoter
DNA methylation strengthened as their location approached the
promoter region, and the strongest signal came from a few SNPs,
exempliﬁed by rs11658063, overlapping with a polycomb
repressive complex 2 (PRC2) mark in embryonic stem cells
(P¼ 0.003; Fig. 3, Supplementary Fig. S8). We validated this
SNP–methylation association in the TCGA data (Supplementary
Fig. S9; see Methods). None of the probes used contained com-
mon SNPs in the sequence, excluding technical artifact as a
confounder of this association.
Overexpression of HNF1B. Given the proposed role of HNF1B in
clear cell tumorigenesis, we stably overexpressed the gene in
immortalized endometriosis epithelial cells (EECs), which are
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hypothesized to be a cell of origin for clear cell ovarian cancers
(Supplementary Fig. S10)18. EECs overexpressing HNF1B acquired
an enlarged, ﬂattened morphology and multi-nucleated cells
accumulated in the cultures (Fig. 4a). Also, signiﬁcant
upregulation of HNF1B-associated genes SPP1, DPP4, and ACE2
was observed upon HNF1B overexpression in EECs (Fig. 4b).
Discussion
HNF1B appears to have a prominent role in ovarian cancer
aetiology. It is the ﬁrst clear cell ovarian cancer-susceptibility gene
identiﬁed, and variation in the gene is also associated with risk of
serous ovarian cancer at a genome-wide signiﬁcance level. The
gene is overexpressed in clear cell tumours and silenced in serous
tumours. The strong association between HNF1B expression
and CIMP methylation (P¼ 3 10 16), and the reciprocal
nature of DNA methylation at the HNF1B-promoter CpG
islands, versus other CpG islands across the genome, suggests
that HNF1B-promoter methylation is not merely a CIMP
passenger event; in fact, HNF1B expression may even contribute
to the hypermethylation phenotype. Taken together, these data
indicate differing roles for HNF1B in these invasive EOC
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Figure 1 | Identiﬁcation of HNF1B as a subtype-speciﬁc candidate gene for ovarian cancer and its establishment as a susceptibility gene. (a) The
scatterplot compares the mRNA expression (y axis) versus DNA methylation (x axis) in serous ovarian tumours from TCGA (see Methods). Each blue dot
is a serous tumour sample, whereas each pink dot is one of the ten normal fallopian tube samples. The HNF1B promoter is silenced in the majority of these
tumours, either by an epigenetic (bottom right, high DNA methylation and low mRNA expression) or an unknown alternative mechanism. The mRNA
expression data were integrated from three platforms (online Methods) and interpreted as log ratios, and we observe the same pattern with each individual
expression platform (Supplementary Fig. S1). (b) HNF1B-promoter DNA methylation differs by histological subtype. Although unmethylated in the normal
fallopian tissue, this locus is hypermethylated (beta value 40.2) in approximately 50% of the TCGA (n¼ 576; see Methods) serous cases as well as
another independent set of 32 serous tumour samples (OCRF panel; see Methods), but remains unmethylated in clear cell tumours (OCRF panel; see
Methods) (n¼4). These data are consistent with reported HNF1B expression in the clear cell tumours. (c) Genetic variants in the HNF1B locus are
associated with risk of ovarian cancer histological subtypes. Plotted in each panel is the  log10 (P-value) from the SNP association with risk for each
subtype (Manhattan plots) located in the 150-kb region described in the text. Imputed SNPs are indicated with a relatively lighter colour, whereas the
genotyped SNPs are indicated with a darker colour. Dashed lines indicate the genome-wide signiﬁcance threshold (5 10 8). The linkage disequilibrium
plot on the bottom shows the r2 between the SNPs. Genomic coordinates are based on hg19 (Build37).
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subtypes: a potential gain-of-function in clear cell ovarian cancer
and loss-of-function in serous ovarian cancer, underscoring the
heterogeneity of this disease.
Different SNPs in the HNF1B gene regions explain the
associations observed for serous and clear cell ovarian cancers.
These different effects provide further support for the growing
view that the histological subtypes of ovarian cancer represent
distinct diseases18–24, with endometriosis as a proposed cell of
origin for clear cell disease18 and fallopian tube ﬁmbriae as one
for serous disease22. Interestingly, no association was observed
between HNF1B genotypes and endometrioid ovarian cancer
despite the view that, like clear cell, endometriosis is also a cell of
origin for this subtype. The lack of association may be due to a
different transformation mechanism from endometriosis for the
endometrioid subtype, given that although the HNF1B promoter
remains unmethylated in the endometrioid subtype, the
endometrioid subtype does not overexpress HNF1B.
Alternatively, misclassiﬁcation of high-grade serous EOC as
high-grade endometrioid could result in a bias towards the null
for the endometrioid subtype.
Variation in the 50 UTR through the intron 4 region of HNF1B
is also associated with susceptibility to prostate12,14–16 and
uterine cancer17 (where minor alleles of certain SNPs are
associated with decreased risk) and type II diabetes12,13
(increased risk for the same or correlated SNP alleles;
Supplementary Fig. S4). The opposing directions of these
associations mirror the differential effects seen here in ovarian
cancer. The most strongly associated SNP for both prostate14 and
uterine cancer17 is rs4430796, correlated at r2¼ 0.94 with the top
clear cell ovarian cancer SNP, rs11651755, suggesting a common
risk variant. Although increased risk of type II diabetes has been
reported with rs4430796 (ref. 12), Winckler et al.13 have
suggested that the best marker of diabetes risk is rs757210,
which correlated at r2¼ 0.97 with our top serous SNP. Thus, the
evidence suggests that a speciﬁc variant in HNF1B predisposes to
clear cell ovarian, uterine and prostate cancers and that a different
variants is associated with diabetes and serous ovarian cancer.
We were able to completely ﬁne-map the HNF1B region, localize
the signal and identify a handful of potentially causal SNPs. This is
quite different from other regions of the genome where it is not
uncommon to identify hundreds of candidate causal SNPs. Further,
an important link, often missing when susceptibility loci are
identiﬁed, is the functional role that the variant has in disease. In
the case of serous ovarian cancer, the SNP–HNF1B-promoter DNA
methylation association strengthens as it approaches the promoter
region, particularly where it overlaps with a PRC2 mark. PRC2–
Table 1 | Association between invasive, serous and clear cell ovarian cancer for ten HNF1B SNPs that reached genome-wide
signiﬁcance in Whites.
All invasive (n¼ 14,533) Serous (n¼8,371) Clear cell (n¼ 1,025)
Reference/
alternate allele Imputed r2 AAF OR 95% CI P-value OR 95% CI P-value OR 95% CI P-value
Univariate
rs3744763* A/G 0.409 1.06 1.03 1.10 1.6 104 1.13 1.09 1.17 4.0 10 10 0.83 0.750.91 7.1 10 5
17-36092841*,w G/GT 0.902 0.403 1.05 1.01 1.08 0.005 1.13 1.08 1.17 3.1 10 9 0.82 0.740.90 5.3 10 5
rs7405776* G/A 0.376 1.05 1.02 1.09 0.001 1.13 1.09 1.17 3.1 10 10 0.80 0.730.88 6.2 10 6
rs757210* C/T 0.372 1.05 1.02 1.09 9.5 104 1.13 1.09 1.17 3.2 10 10 0.80 0.730.88 4.1 10 6
rs4239217* A/G 0.402 1.04 1.01 1.07 0.018 1.11 1.07 1.16 2.6 10 8 0.79 0.720.87 1.0 10 6
rs11651755* T/C 0.489 1.02 0.99 1.06 0.124 1.10 1.06 1.14 9.9 10 7 0.77 0.700.84 1.6 10 8
rs61612821w T/C 0.827 0.140 1.09 1.04 1.14 4.1 104 1.19 1.13 1.26 1.1 10 9 0.79 0.680.92 0.002
rs11657964* G/A 0.400 1.04 1.01 1.08 0.006 1.12 1.08 1.16 5.3 10 9 0.80 0.730.88 4.6 10 6
rs7501939* C/T 0.400 1.04 1.01 1.08 0.006 1.12 1.08 1.16 4.8 10 9 0.80 0.730.88 3.7 10 6
rs11658063z G/C 0.963 0.398 1.05 1.02 1.08 0.003 1.12 1.08 1.17 1.8 10 9 0.81 0.740.90 2.3 10 5
Bivariate
rs7405776 G/A 1.11 1.06 1.18 9.8 10 5 0.95 0.83 1.09 0.470
rs11651755 T/C 1.02 0.96 1.07 0.580 0.80 0.700.91 7.0 104
AAF, alternate allele frequency; CI, conﬁdence interval.
*Genotyped.
wInsertion.
zImputed.
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Figure 2 | HNF1B-promoter DNA methylation, protein expression and
global DNA-methylation pattern by subtype. Each row is a tissue sample
collected at the Mayo Clinic that belongs to one of the three categories:
normal ovarian tissue (n¼ 7), clear cell ovarian tumours (n¼ 17) or serous
ovarian tumours (n¼ 196). Endometrioid (n¼49) and mucinous (n¼ 7)
tumours are not included in this ﬁgure. Each column represents a CpG
locus, either from the region ﬂanking the HNF1B transcription start site
(panel A, ordered by genomic locations with an arrow indicating the
transcription start site) or from a global panel of 1,003 CpG loci mapped
to autosomal CpG island regions that distinguish clear cell and serous
subtypes (panel B, ordered by average DNA methylation across the
samples). For each horizontal panel group, the samples (rows) are ordered
by HNF1B IHC status. The heatmap shows the DNA-methylation beta
value, with blue indicating low DNA methylation and red indicating high
methylation. Clear cell tumours showed less DNA methylation at the
HNF1B-promoter region and correspondingly higher HNF1B protein
expression. The clear cell tumours generally show a CIMP where there is
extensive gain of aberrant promoter methylation in a correlated manner.
CIMP status (left side bar, deﬁned as methylated at 480% of the 1,003
loci) is highly correlated HNF1B expression. Also noteworthy is that the
HNF1B-promoter DNA methylation (panel a) is the opposite from the global
pattern (panel b, Supplementary Fig. S8). This suggests HNF1B DNA
methylation is not a passenger event of global DNA-methylation changes.
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DNA methyltransferase cross-talk has been proposed to be a
mechanism of predisposition to cancer-speciﬁc hypermethylation25.
Our DNA-methylation data indicate that the causal risk alleles for
the serous subtype may predispose the promoter to acquiring
aberrant methylation, thereby promoting the development of serous
but not clear cell tumours. This predisposition could be a direct
functional effect of the SNP on the DNA-methylation machinery,
or could act indirectly through differential binding afﬁnity for PRC2
or one or more transcription factors. Given that we were able to
ﬁne-map the HNF1B region, it is unlikely that an unidentiﬁed
common variant explains these associations. For serous ovarian
cancer, the methylation signal suggests that the causal variant is
most likely to be among those located within the region with the
PRC2 mark for which we identiﬁed ﬁve SNPs with genome-wide
signiﬁcance.
This is the ﬁrst study investigating the effects of overexpression
of HNF1B in endometriosis, and the results support the
hypothesis that HNF1B may have an oncogenic role in the
initiation of clear cell ovarian cancers, as speculated by Gounaris
et al.23 as a key step of endometriosis transformation. The
observation in our data that HNF1B induces a polynucleated
phenotype in EEC cells is intriguing, as clear cell ovarian cancers
are often tetradiploid, more so than other ovarian cancer
subtypes26. The polynucleated phenotype may suggest that
HNF1B overexpression in EECs perturbs cytokinesis, causing
aneuploidy in some cells.
Histology re-review of the three clear cell tumours that do not
express HNF1B revealed two scenarios: two samples with
inconsistent evaluations between pathologists, and one consis-
tently called clear cell. They might be cases that are especially
difﬁcult to classify, and therefore a molecular signature, for
example, CIMP or HNF1B status, would be of great help in
correctly classifying those tumours. The one sample that is called
consistently clear cell tumour but does not express HNF1B might
represent a rare subtype of clear cell carcinoma. With a larger
cohort of clear cell ovarian cancers, these possibilities can be
investigated.
To our knowledge, this is the ﬁrst report of tumour DNA-
methylation patterns leading to the identiﬁcation of a germline
susceptibility locus, underscoring the value of TCGA. Recent
studies suggest a strong genetic component to inter-individual
variation in tumour DNA methylation, and demonstrate both
cis- and trans- associations between genotypes and DNA
methylation27. In addition, methylation quantitative trait loci
were found to be enriched for expression quantitative trait loci. It
has also been shown that epimutation is associated with genetic
variation, for example, associations have been demonstrated
between 50 UTRMLH1 variants andMLH1 epigenetic silencing28.
Moreover, we have for the ﬁrst time demonstrated the existence
of a CIMP phenotype in ovarian cancer, highlighting the
complicated nature of the disease.
In summary, variation in HNF1B is associated with serous and
clear cell subtypes of ovarian cancer in opposite manner at
genetic, epigenetic and protein expression levels. These observa-
tions are compatible with a tumour suppressor role in serous
cancer and an oncogenic role in clear cell disease. Future efforts
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should focus on understanding these mechanisms as they could
have major clinical implications for ovarian cancer, based on
better subtype stratiﬁcation, potential novel treatment approaches
and a better understanding of disease aetiology. Currently,
effective chemotherapeutics for clear cell ovarian cancer is
lacking, but our study reveals that HNF1B-expressing clear cell
tumours have extensive epigenetic alterations that potentially
make them good candidates for epigenetic therapies.
Methods
Molecular aspects
TCGA data access. We downloaded the TCGA serous ovarian cancer data
packages from the TCGA public-access ftp (ohttps://tcga-data.nci.nih.gov/
tcgaﬁles/ftp_auth/distro_ftpusers/anonymous/tumour/ov/4). Data generated
with the following platforms were used: Affymetrix HT Human Genome U133
Array Plate Set; Agilent 244K Custom Gene Expression G4502A-07-3; Affymetrix
Human Exon 1.0 ST Array; and Illumina Inﬁnium HumanMethylation27 Beadchip
(a full list of the packages is provided in Supplementary Methods).The Illumina
Human1M-Duo DNA Analysis BeadChip Genotype data were downloaded from
the controlled access data tier.
DNA methylation data production for the OCRF tumour panel. The Illumina
Inﬁnium HumanMethylation27 assay was performed as described9 on
32 serous and 4 clear cell ovarian tumours from USC Norris Comprehensive
Cancer Center and Duke University (‘OCRF tumour panel’). The beta values for
each sample and locus were calculated with mean non-background corrected
methylated (M) and unmethylated (U) signal intensities with the formula M/
(MþU), representing the percentage of methylated alleles. Detection P-values
were calculated by comparing the set of analytical probe replicates for each locus to
the set of 16 negative control probes. Data points with detection P-values 40.05
were masked.
DNA methylation data production for the Mayo tumour panel. We also
performed the Inﬁnium HumanMethylation450 BeadChip assay on an
independent set of tumour DNA in the Mayo Clinic Genotyping Shared Facility
using recommended Illumina protocol29. 1 mg of tumour DNA was bisulﬁte-
converted using the Zymo EZ96 DNA Methylation Kit. Three samples failing
quality control were removed, leaving DNA-methylation data on 333 ovarian
cancer cases, including 254 serous and 17 clear cell tumours. Plate normalization
was done with a linear model on the logit-transformed beta values, following back-
transformation to the (0,1) range.
IHC assay. Previously built tissue microarrays, triplicate core, measuring 0.6mm
were cut at 4-mm thickness and mounted on superfrost slides. Slides were stained
on a Ventana Benchmark XT using the manufacturer’s pretreatment protocol
CC1 standard (Supplementary Methods). A pathologist (MK) evaluated the IHC
staining, and assigned the sample a score 0 in the absence of any nuclear staining,
score 1 for any nuclear staining 41–50% or score 2 for 450% tumour cell
nuclei-positive for HNF1B.
Genotype and DNA methylation association. We assessed the correlation
of germline genotype at the nine genome-wide signiﬁcant SNPs in serous cancer,
with HNF1B DNA promoter methylation status using the Mayo Tumour Panel.
Probe cg14487292 was used as it was most inversely correlated with mRNA
expression. The nominal P-values are from two-sided tests for linear trend in the
DNA-methylation beta values across the three genotypes for each locus. Bonferroni
adjustment was not done for multiple comparisons as the SNPs are highly
correlated. Validation was done with the TCGA data (Supplementary Appendix).
In vitro model of HNF1B overexpression. An immortalized EEC line was
generated by lentiviral transduction of hTERT (Addgene plasmid 12245) into
primary EECs (Supplementary Fig. S10). TERT-immortalized EECs were
transduced with lentiviral HNF1B-green ﬂuorescent protein (GFP) or GFP
(Genecopoeia) supernatants and positive cells selected with 400 ngml 1
puromycin (Sigma). GFP expression was conﬁrmed by ﬂuorescent microscopy;
HNF1B expression was conﬁrmed by real-time PCR (Supplementary Fig. S10).
For gene-expression studies, RNA was collected from cells using the Qiagen
RNeasy kit with on-column DNase I digestion. An amount of 1 mg RNA was
reverse transcribed using an MMLV reverse transcriptase enzyme (Promega), and
relative mRNA level was assayed using the ABI 7900HT Fast Real-Time PCR
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Figure 4 | Phenotypic effects and downstream targets of HNF1B overexpression in immortalized EECs. (a) Morphological changes in EECs expressing
a HNF1B GFP fusion protein (EECGFP.HNF1B). GFP-positive cells were sorted using ﬂow cytometry. The arrows indicate ﬁve nuclei contained within
a single EECGFP.HNF1B cell, showing the aberrant polynucleation that we observed in these cells. Using ﬂow cytometry, we quantiﬁed the increase in
polynucleation in EECGFP.HNF1B to be around eightfold compared with controls (data not shown). (b) Gene-expression analysis of HNF1B-target genes
and clear cell ovarian cancer associated genes. *P40.01.
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system utilizing the delta-delta Ct method. Statistical analyses were performed
using Prism. Two-tailed paired t-tests with signiﬁcance level of 0.05 were used.
Genetic association study
Study design. The genetic susceptibility aspect of this study was organized by
the Collaborative Oncological Gene-Environment Study, an ovarian, breast and
prostate cancer consortium. The ovarian cancer part of this effort on which the
current report is based is led by the Ovarian Cancer Association Consortium and
included 43 studies (Supplementary Table S1). Following sample quality control,
44,308 subjects, including 16,111 patients with invasive EOC, 2,063 with low
malignant potential (borderline) disease and 26,134 controls, were available for
analysis; results presented here are restricted to invasive cancers. All studies
obtained approval from their respective human research ethics committees,
and all participants provided written informed consent.
Selection of SNPs. Data for 174 SNPs in this region were available from
the Collaborative Oncological Gene-Environment Study genotyping effort and
provided full ﬁne-mapping information in the 150-kb region surrounding HNF1B
(hg18 coordinates 33,100,000–33,250,000). In addition, phase I haplotype data
from the 1000 Genomes Project (January 2012) were used to impute genotypes for
SNPs across this region, resulting in available data on an additional 307 SNPs
with MAF 40.02 in European Whites and imputation r240.30 (IMPUTE 2.2).
SNP genotyping. The Ovarian Cancer Association Consortium genotyping
was conducted by McGill University and Ge´nome Que´bec Innovation Centre
(n¼ 19,806) and the Mayo Clinic Medical Genome Facility (n¼ 27,824) using an
Illumina Inﬁnium iSelect BeadChip. Genotypes were called using GenCall. Sample
and SNP quality-control measures are described in the Supplementary Methods.
Statistical analysis. We used the program LAMP30 for principal components
analysis to assign intercontinental ancestry based on the HapMap (release no. 22)
genotype frequency data for European, African and Asian populations
(Supplementary Methods). For LAMP-derived European ancestry groups for all
patients of invasive cancer and for those with serous invasive cancer, we carried out
unconditional logistic regression analyses within each study site, adjusted for the
ﬁrst ﬁve eigenvalues from the principal components analysis for European ancestry
and then used a ﬁxed-effects meta-analytic approach to obtain the summary
OR estimate, 95% conﬁdence interval and P-value. Details on analysis for the
non-European groups are provided in the Supplementary Methods. Log-additive
mode of inheritance was modelled (that is, co-dominant), treating each SNP as an
ordinal variable.
For haplotype analysis, we used the tagSNPs program31 to obtain the haplotype
dosage for each subject for the LAMP-derived European ancestry group for
haplotypes with a frequency ofZ1%. The associations between haplotype and risks
of serous and clear cell ovarian cancer were modelled by meta-analysis relative to
the most common haplotype.
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